Table 1.
Immune cell populations predicting efficacy in lung cancer medical treatments (including cells function and references).
| Immune biomarker | Definition | Location | Outcome | References |
|---|---|---|---|---|
| Treg/ CD8+ ratio | CD4+ FoxP3+ | Tumor | ↑ Chemo response rate | (75) |
| Tertiary Lymphoid Structures | B cells, DCs, CD4+ CD8+ T cells | Tumor | ↑ Chemo PFS | (77) |
| “Teff” lymphocytes signature | PD-L1, CXCL9, and IFNγ mRNA | Tumor | ↑ ICB PFS/OS (signature] | (87) |
| “Dormant” lymphocytes | CD3+ Granzyme B− Ki67− | Tumor | ↑ ICB response rate | (20) |
| CD4+ highly differentiated | CD27− CD28low/− | Blood | ↑ ICB response rate | (93) |
| PDL1+ immune cells | PDL1+ macro, DCs, lymphocytes | Tum/Blood | ↑ ICB response rate | (83, 84, 92) |
| “Reactivated” lymphocytes | CD8+ PD1+ Ki67+ | Blood | ↑ ICB response rate | (99) |
| Neutrophil lymphocyte ratio (NLR] | Neutrophil/Lymphocyte | Blood | ↓ Chemo PFS/OS (high NLR] | (80) |
| Lung immune prognostic index (LIPI] | dNLR >3; LDH > ULN | Blood | ↓ ICB PFS/OS (high LIPI] | (90) |
| Myeloid derived suppressor cells | CD33+ HLADR− CD11b+ | Blood | ↓ Chemo/ICB response rate | (78, 98) |
Data are presented for published studies (not for abstract only). Immune populations with a positive or detrimental outcome are highlighted in green or red, respectively. CXCL9, chemokine (C-X-C motif) ligand 9; DCs, dendritic cells; IFN, interferon; Chemo, chemotherapy; ICB, immune checkpoint blockade; NLR, neutrophil-to-lymphocyte ratio; PD-1, programmed death 1; PDL-1, programmed death ligand 1; PFS, progression-free survival; OS, overall survival, w, weeks.